Assessment of the Quality and Quantity of Drug‐Drug Interaction Studies in Recent NDA Submissions: Study Design and Data Analysis Issues
Authors:
- 1 October 1999
- journal article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 39 (10) , 1006-1014
Abstract
This report investigates the quality and quantity of drug‐drug interaction studies in recent new drug applications (NDAs). Eighty‐nine studies contained in 14 NDAs submitted between December 1995 and November 1996 to the U.S. Food and Drug Administration (FDA) were reviewed. The results indicated that the median number of clinical drug‐drug interaction studies per NDA was 6, almost double that of a 1994–1995 survey. In vitro metabolism data were present in 70% of the submissions. More than 50% of the submissions contained interaction studies using a battery of drugs (cimetidine, digoxin, or warfarin) without optimal use of the in vitro metabolism or in vivo mass balance data. Various study designs using a median number of 12 subjects were employed in the evaluation of drug‐drug interactions. Some of the important study design factors such as dose size, dosing regimen, dosing duration, and timing of coadministration were considered, although not consistently, by the sponsors in their study design. Seventy‐five percent of the studies used normal, healthy male subjects, and 25% used patients for whom the new molecular entities were intended. In 33% of the studies, female subjects were also recruited. Although the majority (80%) of the submissions still used p‐values to determine the significance of drug interactions, 30% used a more relevant equivalence approach with 90% confidence intervals for key pharmacokinetic and/or pharmacodynamic parameter ratios to assess the extent of drug interactions. Overall, 82% of the studies concluded no interaction. Although population pharmacokinetic analysis can be a useful tool in studying drug‐drug interactions, only 21% of the submissions used this approach. In summary, this assessment reveals that the quantity and quality of drug‐drug interaction studies in NDAs have improved over the years. These improvements, as well as others that can be implemented, should result in more informative labeling and better patient care. FDA guidance for industry dealing with the design, analysis, and labeling language of in vivo metabolic drug‐drug interactions has been developed to assist sponsors and FDA reviewers with these issues.Keywords
This publication has 21 references indexed in Scilit:
- Grapefruit juice (GFJ) has a small effect on lovastatin plasma HMG-CoA reductase inhibitor (HMGRI) profilesClinical Pharmacology & Therapeutics, 1999
- Mibefradil is a potent inhibitor of both CYP3A and P-glycoprotein (P-gp)Clinical Pharmacology & Therapeutics, 1999
- Nevirapine induces both CYP3A4 and CYP2B6 metabolic pathwaysClinical Pharmacology & Therapeutics, 1999
- Life-Threatening Interaction of Mibefradil and β-Blockers With Dihydropyridine Calcium Channel BlockersJAMA, 1998
- What lessons can be learnt from withdrawal of mibefradil from the market?The Lancet, 1998
- Two New Warnings Added to Labeling for Mibefradil1998
- Antiretroviral Therapy for HIV Infection in 1997JAMA, 1997
- Lack of interaction between meloxicam and warfarin in healthy volunteersEuropean Journal of Clinical Pharmacology, 1997
- Incidence of Adverse Drug Events and Potential Adverse Drug EventsJAMA, 1995
- Terfenadine-Ketoconazole InteractionJAMA, 1993